June 27, 2025

Health-Related QOL With Belzutifan vs Everolimus in Advanced Renal Cell Carcinoma

In a health-related quality of life (QOL) analysis reported in The Lancet Oncology, Powles et al found that belzutifan was associated with better QOL on patient-reported outcomes vs everolimus in pati...

The ASCO Post

June 27, 2025

Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?

Researchers examined whether a urine test could accurately detect clear cell renal cell carcinoma recurrence at an early stage, according to findings presented at the European Association of Urology (...

The ASCO Post

June 27, 2025

Belzutifan Plus Cabozantinib as First-Line Treatment in Advanced Clear Cell Renal Cell Carcinoma

In the phase II LITESPARK-003 trial, reported in The Lancet Oncology, Choueiri et al found that the combination of belzutifan—a first-in-class HIF-2α inhibitor—and cabozantinib showed promising activi...

The ASCO Post

June 27, 2025

Novel Personalized Cancer Vaccine May Be Effective in Patients With Stage III and IV Clear Cell Renal Cell Carcinoma

Researchers have examined whether a novel personalized cancer vaccine can improve outcomes in patients with stage III or IV clear cell renal cell carcinoma.

The ASCO Post

November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

May 09, 2024

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, a new treatment for unresectable locally advanced or metastatic clear cell renal cell carcinoma was approved, showing favorable outcomes compared to existing therapy.

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 05, 2023

Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study

Dana-Farber